Real-oWorld Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation

被引：0
|
作者：
Yan, Vincent K. C. [1 ]
Yu, Yang [1 ]
Wan, Eric Y. F. [2 ,3 ]
Wong, Ian Chi Kei [1 ]
Chan, Esther W. [1 ]
机构：
[1] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Ctr Safe Medicat Practice & Res, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Dept Family Med & Primary Care, Hong Kong, Peoples R China
[3] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
496
引用
收藏
页码：202 / 202
页数：1
相关论文
共 50 条
  • [21] Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: A target trial emulation
    Richards-Belle, Alvin
    Launders, Naomi
    Hardoon, Sarah
    Richards, Al
    Man, Kenneth K. C.
    Davies, Neil M.
    Bramon, Elvira
    Hayes, Joseph F.
    Osborn, David P. J.
    PLOS MEDICINE, 2025, 22 (01)
  • [22] Real-world effectiveness and safety of tixagevimab/cilgavimab lower dosage regimen in pre-exposure prophylaxis in patients undergoing treatment for chronic lymphocytic leukemia
    Simkovic, Martin
    Ecsiova, Dominika
    Vodarek, Pavel
    Maly, Josef
    Smolej, Lukas
    Rozsivalova, Petra
    LEUKEMIA & LYMPHOMA, 2023, 64 : S173 - S174
  • [23] Efficacy and Safety of Tixagevimab-Cilgavimab (Evusheld or AZD7442) As Pre-Exposure Prophylaxis for COVID-19 Among Allogeneic Hematopoietic Stem Cell Transplant Recipients
    Do, Quan
    Bahaj, Waled
    Chandler, Natasha
    Chao, Ju-Hsien
    Emmons, Robert V. B.
    Hegazi, Mohamed
    BLOOD, 2023, 142
  • [24] Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
    Forte-Soto, Pablo
    Albayaty, Muna
    Brooks, Dennis
    Arends, Rosalinda H.
    Tillinghast, John
    Aksyuk, Anastasia A.
    Bouquet, Jerome
    Chen, Cecil
    Gebre, Asfiha
    Kubiak, Robert J.
    Reddy, Venkatesh Pilla
    Seegobin, Seth
    Streicher, Katie
    Templeton, Alison
    Esser, Mark T.
    JOURNAL OF INFECTIOUS DISEASES, 2023, 227 (10): : 1153 - 1163
  • [25] Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
    Hites, Maya
    Lapique, Eva Larranaga
    Massonnaud, Clement R.
    Belhadi, Drifa
    Jamard, Simon
    Goehringer, Francois
    Danion, Francois
    Reignier, Jean
    de Castro, Nathalie
    Garot, Denis
    Lacombe, Karine
    Tolsma, Violaine
    Faure, Emmanuel
    Malvy, Denis
    Staub, Therese
    Courjon, Johan
    Cazenave-Roblot, France
    Riise, Anne Ma Dyrhol
    Leturnier, Paul
    Martin-Blondel, Guillaume
    Roger, Claire
    Akinosoglou, Karolina
    Le Moing, Vincent
    Piroth, Lionel
    Sellier, Pierre
    Lescure, Xavier
    Troseid, Marius
    Clevenbergh, Philippe
    Dalgard, Olav
    Gallien, Sebastien
    Gousseff, Marie
    Loubet, Paul
    Vardon-Bounes, Fanny
    Visee, Clotilde
    Belkhir, Leila
    Botelho-Nevers, Elisabeth
    Cabie, Andre
    Kotanidou, Anastasia
    Lanternier, Fanny
    Rouveix-Nordon, Elisabeth
    Silva, Susana
    Thiery, Guillaume
    Poignard, Pascal
    Carcelain, Guislaine
    Diallo, Alpha
    Mercier, Noemie
    Terzic, Vida
    Bouscambert-Duchamp, Maude
    Gaymard, Alexandre
    Trabaud, Mary-Anne
    JOURNAL OF INFECTION, 2024, 88 (03)
  • [26] Comparative effectiveness and safety of BNT162b2 and CoronaVac in Hong Kong: A target trial emulation
    Wan, Eric Yuk Fai
    Wang, Boyuan
    Lee, Amanda Lauren
    Zhou, Jiayi
    Chui, Celine Sze Ling
    Lai, Francisco Tsz Tsun
    Li, Xue
    Wong, Carlos King Ho
    Hung, Ivan Fan Ngai
    Lau, Chak Sing
    Chan, Esther Wai Yin
    Wong, Ian Chi Kei
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2024, 146
  • [27] Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study
    Buaboonnam, Jassada
    Rungmaitree, Supattra
    Piyaphanee, Nuntawan
    Charuvanij, Sirirat
    Pitisuttithum, Onsiri
    Copeland, Katherine
    Pheerapanyawaranun, Chatkamol
    Jansarikit, Laddawan
    Niyomnaitham, Suvimol
    Chokephaibulkit, Kulkanya
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [28] Comparative Effectiveness of Second-line ADHD Medications Using Real World Data: Emulation of a Target Trial
    Zhang, Le
    Zhu, Nanbo
    Kuja-Halkola, Ralf
    D'Onofrio, Brian M.
    Brikell, Isabell
    Lichtenstein, Paul
    Larsson, Henrik
    Chang, Zheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 113 - 114
  • [29] Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation
    Akenroye, Ayobami T.
    Segal, Jodi B.
    Zhou, Guohai
    Foer, Dinah
    Li, Lily
    Alexander, G. Caleb
    Keet, Corinne A.
    Jackson, John W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (05) : 1269 - 1276
  • [30] The comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation
    Akenroye, Ayobami
    Segal, Jodi
    Zhou, Guohai
    Foer, Dinah
    Li, Lily
    Alexander, G. Caleb
    Keet, Corinne
    Jackson, John
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB19 - AB19
12345